Atherosclerotic plaque formation results from chronic inflammation and fibroproliferative remodeling in the vascular wall. We previously demonstrated that both human and mouse atherosclerotic plaques show elevated expression of EphA2, a guidance molecule involved in cell-cell interactions and tumorigenesis.
A therosclerosis, a chronic inflammatory disease of the large arteries, involves the focal accumulation of low-density lipoproteins (LDL) in the vessel intima, stimulating endothelial cell activation and macrophage recruitment. As lipid accumulates, macrophage clearance of LDL becomes dysfunctional, resulting in foam cell formation visible histologically as fatty streaks. Smooth muscle fibroproliferative remodeling critically regulates the progression of atherosclerosis from early fatty streaks to advanced atheromas. 1 As fatty streaks form, underlying medial smooth muscle cells undergo a phenotypic transition from their contractile, quiescent phenotype to a synthetic phenotype characterized by reduced contractile gene expression, enhanced cell proliferation and migration, and heightened deposition of extracellular matrix proteins. 2 Although this fibroproliferative remodeling can be deleterious by enhancing plaque size to promote stenotic lesions, formation of a protective fibrous cap over the necrotic core of the plaque provides stability to the plaque by preventing rupture and thrombosis. 1 The Eph family of receptor tyrosine kinases, the largest family in the mammalian genome, interact with ephrin ligands on adjacent cells to mediate cell adhesion/repulsion signaling during axonal guidance, tissue patterning, leukocyte homing, and metastasis. 3 The 14 mammalian Eph receptors are divided between 9 EphA receptors (EphA1-8, A10) and 5 EphB (EphB1-4, B6) receptors based on sequence homology and ligand binding preferences. 3 With some exceptions, EphA receptors interact predominantly with GPI-linked ephrinA ligands (ephrinA1-5), whereas EphB receptors interact predominantly with transmembrane ephrinB ligands (ephrinB1-3).
Accumulating evidence suggests that Eph/ephrin interactions regulate various aspects of inflammation. 4 Multiple Ephs and ephrins show enhanced expression during endothelial cell activation, including ephrinB2, ephrinA1, and EphA2. 5, 6 Activation of EphA2 promotes endothelial intercellular cell adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) expression in response to several stimuli, 6, 7 whereas activation of EphA4 enhances endothelial stiffness to promote monocyte binding. 8 In addition to endothelial activation, Eph/ephrin interactions affect leukocyte adhesion to the activated endothelium. Monocyte EphB2 receptors bind ephrinB2 on activated endothelial cells, resulting in enhanced monocyte adhesion. 5 Similarly, ligation of ephrinA ligands by endothelial EphA receptors promotes lymphocyte integrin activation and firm adhesion. 4 In addition to leukocyte homing, activation of macrophage EphB receptors enhances interleukin-8 and monocyte chemotactic protein-1 expression, suggesting that Eph/ephrin signaling affects leukocyte function. 5 We previously demonstrated enhanced endothelial and macrophage EphA2 expression in both human and murine atherosclerotic plaques, 6 and Jiang et al 9 showed that injecting EphA2 shRNA into atherosclerosis-prone Apoe −/− mice reduced plaque formation. The EphA2 gene is located at the 1p36 locus in humans, 10 which is linked to premature myocardial infarction, 11 and the athsq1 locus in mice, which is linked to susceptibility to atherosclerosis. 12 However, the contributions of EphA2 to vascular disease remain poorly characterized. The data herein define novel, multifactorial effects of EphA2 deletion on atherosclerotic plaque formation.
METHODS
An expanded Material and Methods section can be found in the online-only Data Supplement.
Clinical Perspective
What Is New?
• Although Eph receptors and their ephrin ligands play well-characterized roles in angiogenesis and cancer, we present the first evidence that deletion of EphA2 in mouse models of atherosclerosis diminishes atherosclerotic plaque formation and limits atherosclerotic plaque progression.
• We demonstrate that EphA2 deletion reduces proinflammatory gene expression and early monocyte recruitment to the plaque, associated with reductions in monocyte firm adhesion under flow.
• We demonstrate the first link between smooth muscle phenotypic modulation and EphA2 expression, and we define a novel role for smooth muscle EphA2 expression in driving smooth muscle proliferation and extracellular matrix deposition.
What Are the Clinical Implications?
• Although EphA2 contributes to monocyte recruitment to the atherosclerotic plaque, EphA2 expression does not affect multiple other monocyte proinflammatory responses, suggesting that blunting EphA2 ligation may selectively reduce plaqueassociated inflammation.
• Although EphA2 expression also contributes to the smooth muscle fibroproliferative remodeling that drives the stable plaque phenotype, the effect of EphA2 on proliferation appears to be largely ligand independent, unlike inflammation. • Blunting EphA2 ligation may limit inflammation while leaving smooth muscle fibroproliferative remodeling intact, thereby promoting a stable plaque phenotype. 
Animal Models and Tissue Harvest

Plaque Analysis and Immunohistochemistry
The aortic root, aorta, innominate artery, and carotid arteries were harvested for analysis of atherosclerotic plaque burden. All paraffin-embedded tissues were sectioned at 5-µm thickness. Stains were visualized on a Nikon Eclipse Ti inverted epifluorescence microscope equipped with a photometrics CoolSNAP120 ES2 camera and NIS Elements 3.00, SP5 imaging software. Analysis was performed with NIS Elements software. Scale bars are provided in figure legends. For detailed information, see Methods in the onlineonly Data Supplement.
Cell Culture and Treatments
Human peripheral blood monocytes were isolated with Percoll and Ficoll density gradients from blood drawn from human donors following a LSU Health Sciences Center Institutional Review Board approved protocol. Peritoneal macrophages were isolated after thioglycollate injection. Human aortic endothelial cells (Lonza) and RAW264.7 macrophages (ATCC) were cultured as previously described. 6, 13 LDL (Intracel) was oxidized as described previously.
14 For detailed information, see Methods in the online-only Data Supplement.
Lipid Uptake
Peritoneal macrophages isolated from mice fed a high-fat Western diet for 8 weeks were stained with Nile Red to assess lipid content. Uptake of Dil-oxidized LDL was also assessed with peritoneal macrophages and quantified with fluorescence microscopy. For detailed information, see Methods in the online-only Data Supplement.
Quantitative Real-Time Polymerase Chain Reaction
Quantitative real-time polymerase chain reaction was performed as described previously. 6 mRNA was extracted with TRIzol reagent, and cDNA was synthesized with the iScript cDNA synthesis kit (BioRad). Quantitative real-time polymerase chain reaction primer sequences can be found in Tables I and  II in 
Immunoblotting and Immunocytochemistry
Cell lysis, Western blotting, and tumor necrosis factor-α (TNF-α) ELISA assays (eBioscience) were performed as described previously. 13, 15 For detailed information, see Methods in the online-only Data Supplement.
Matrix Deposition Analysis
Deoxycholate extraction was performed as described previously. 16 For detailed information, see Methods in the onlineonly Data Supplement.
Statistical Analyses
All statistical analyses were performed with GraphPad Prism Software. The number of experiments performed and statistical test used are provided in the figure legends. Values are expressed as mean±SEM. For detailed information, see Methods in the online-only Data Supplement. For the initial analysis, both male and female mice were used to assess sex-specific differences in plaque formation after EphA2 deletion. However, both male and female EphA2 KO mice showed reduced atherosclerotic plaque formation at the 8-and 12-week time points as assessed by Oil Red O staining of the mouse aorta ( Figure 1A through 1D) , so subsequent analysis focused on plaque characterization in male mice. Although effects on plaque formation may differ by vascular site, 17 plaque area in cross sections of the innominate artery and carotid sinus were similarly reduced in male EphA2 KO mice, suggesting that EphA2 deletion reduces atherosclerosis across multiple vascular beds ( Figure 1E and 1F) . Although EphA2 KO mice showed a predilection for smaller plaques ( Figure IA in Figure IIB in the online-only Data Supplement) compared with EphA2 WT controls. Furthermore, despite reductions in atherosclerotic plaque formation, analysis of plasma lipids levels showed elevated total cholesterol, high-density lipoprotein cholesterol, and plasma triglycerides in male EphA2 KO mice compared with EphA2 WT mice ( Figure IIC in the online-only Data Supplement), whereas female mice demonstrated a similar lipid profile between the 2 groups. Similarly exacerbated plasma lipid profiles were observed in male EphA2 KO mice, but not female EphA2 KO mice, fed a standard chow diet ( Figure IID in the online-only Data Supplement). The similar reduction in plaque size between male and female EphA2 KO mice suggests that the slight elevation in plasma high-density lipoprotein observed in male EphA2 KO mice likely does not contribute to the atheroprotective effect.
RESULTS
EphA2 Deletion Reduces Plaque Size in Multiple Vascular Beds
EphA2 Deletion Reduced Macrophage Accumulation and Inflammatory Gene Expression In Vivo
Because EphA2 has been implicated in inflammation in a variety of systems, 6 we compared leukocyte accumulation and proinflammatory gene expression during early atherogenesis between EphA2 WT and EphA2 KO mice. After 8 weeks of a Western diet, macrophage area (Mac2 positive) was reduced in atherosclerotic lesions from EphA2 KO mice in both the innominate and carotid arteries compared with EphA2 WT mice (Figure 2A and 2B ). Similar reductions in plaque area and macrophage area were observed in the aortic root of EphA2 KO mice, consistent with the reduction in plaque formation observed by Jiang et al 9 after EphA2 siRNA injection ( Figure IC through IG in the online-only Data Supplement). mRNA isolated from the atherosclerosis-prone aortic arch of EphA2 WT mice showed elevated CD68 expression (macrophage marker) and CD3 expression (T cells) compared with the atherosclerosis-resistant thoracic aorta (Figure 2C) ; however, this induction was significantly reduced in EphA2 KO mice, indicative of reduced leukocyte content. In addition, markers of endothelial activation (ICAM-1, VCAM-1) showed a similar reduction in EphA2 KO mice compared to EphA2 WT mice ( Figure 2D ). Together, these data suggest that EphA2 deletion reduces endothelial activation and leukocyte accumulation during early atherosclerosis.
Deletion of EphA2 Has No Effect on Macrophage Gene Expression or Lipid Uptake In Vitro
Because plaque macrophages express EphA2, 6 we next sought to determine whether EphA2 contributes to macrophage function and gene expression. We assessed the Eph/ephrin gene expression profile and observed similar expression profiles in human peripheral blood monocytes, murine peritoneal macrophages, and the RAW264.7 human macrophage cell line, with prominent monocyte/macrophage expression of EphA2, EphA4, and ephrinA1 ( Figure IIIA in the online-only Data Supplement). However, bone marrowderived macrophages and the THP-1 monocyte-like cell line showed a disparate Eph/ephrin expression profile, limiting their usefulness for assessing EphA2 function in macrophages ( Figure IIIA in the online-only Data Supplement). Thioglycollate-elicited peritoneal macrophages isolated from EphA2 KO mice showed ablated EphA2 expression without compensatory upregulation of EphA4 ( Figure 3A ). In contrast, ephrinA1 expression was enhanced in EphA2 KO mice, consistent with previous studies suggesting antagonistic expression patterns between EphA2 and ephrinA1. 20 Because EphA2 deletion has shown both positive and negative effects on leukocyte homing in multiple model systems, 4 we analyzed macrophage infiltration after thioglycollate-induced sterile inflammation in the peritoneal cavity. Although Western diet-fed mice exhibited enhanced peritoneal macrophage recruitment in both models, there was no difference in macrophage recruitment between EphA2 KO mice and EphA2 WT mice regardless of diet ( Figure 3B (Figure 3I) , and siRNA-mediated EphA2 knockdown in RAW264.7 macrophages did not affect TNF-α induction by oxidized LDL ( Figure IVA and IVB in the onlineonly Data Supplement). Similarly, EphA2 KO peritoneal macrophages and EphA2-depleted RAW264.7 macrophages showed no deficiency in Dil-oxidized LDL uptake ( Figure 3J and Figure IVC in the onlineonly Data Supplement), and peritoneal macrophages from EphA2 KO mice and EphA2 WT mice showed no difference in lipid uptake, identified by Nile Red staining, after Western diet feeding ( Figure 3K and 3L). Taken together, these data suggest that EphA2 signaling does not significantly affect macrophage phenotype, proinflammatory gene expression, or lipid uptake. Results are normalized to Rpl13a and expressed as a fold change compared with unstimulated conditions. n=4. I, Peritoneal macrophages were treated with lipopolysaccharide (LPS; 100 ng/mL, 24 hours), and TNF-α gene expression was quantified by qRT-PCR and normalized to GAPDH. n=6. J, Uptake of Dil-oxidized low-density lipoprotein (Dil-oxLDL; 20 µg/mL, 4 hours) by WT and KO peritoneal macrophages was assessed. n=4. K and L, WT and KO mice were fed WD for 8 weeks, and the lipid levels in peritoneal macrophages was assessed by Nile Red staining, n=5 to 6. Scale bar=100 µm. Data are expressed as mean±SEM. Statistical comparisons were made with 2-way (B and I) or 1-way (C-H) ANOVA with Bonferroni posttest or Student t test (J and K).
Deletion of EphA2 Confers Protection Against Atherosclerosis in Resident Lineages Compared With Hematopoietic Lineage
To determine the specific contributions of EphA2 in hematopoietic or resident cell lineages in vivo, bone marrow chimeras were generated and atherosclerotic plaque formation was assessed after 12 weeks on a Western diet. Alterations in hematopoietic EphA2 expression did not affect plasma lipid levels in this model, suggesting that the disparate lipid profile likely derives from changes in hepatic lipid handling and not altered reverse cholesterol transport ( Figure V in the online-only Data Supplement). Consistent with our in vitro data suggesting EphA2 does not significantly affect macrophage function, EphA2 KO mice still showed reduced plaque formation when reconstituted with EphA2 WT bone marrow ( Figure 4A and 4B), whereas EphA2 WT mice reconstituted with EphA2 KO bone marrow showed only minor, insignificant reductions compared with reconstitution with EphA2 WT marrow.
Cross-sectional analysis of atherosclerotic plaques in the innominate artery showed significant reductions in plaque size only when EphA2 was deleted in resident lineages and not with EphA2-deleted bone marrow ( Figure 4C and 4D). Similarly, plaque macrophage area was significantly reduced in EphA2 KO mice even when reconstituted with EphA2 WT bone marrow ( Figure 4C and 4E), whereas plaque macrophage content was unaltered in EphA2 WT mice whether reconstituted with EphA2 WT or EphA2 KO marrow. Although these data suggest that vascular EphA2 expression plays a primary role in regulating atherosclerotic inflammation, we cannot rule out a role for EphA2 expression in macrophages because no statistically significant differences were observed between EphA2 deletion in the recipient mice and EphA2 deletion in the marrow-derived cells. Supporting a primary role for endothelial EphA2 in atherogenic inflammation, EphA2 Figure 3B ). Taken together, these data suggest that endothelial EphA2 contributes to monocyte recruitment into atherosclerotic lesions.
EphA2 Deletion Attenuates Progression to Advanced Atherosclerotic Plaques
Although EphA2 deletion did not affect the stage of plaque progression at early time points after Western diet feeding (8 weeks), we next investigated whether EphA2 contributes to plaque progression to advanced atherosclerosis after 16 weeks of Western diet feeding. Consistent with earlier time points, deletion of EphA2 reduced plaque area as demonstrated by Oil Red O staining of the aorta ( Figure 5A and 5B). Analysis of plaque stage with the Stary scoring system revealed a reduced incidence of advanced atheromas (type III and IV plaques) in EphA2 KO mice compared with EphA2 WT controls ( Figure 5C ). The reduction in plaque progression was associated with attenuated smooth muscle actin-positive smooth muscle area in the atherosclerotic lesions from the innominate artery, carotid artery ( Figure 5D through 5F), and aortic root (Figure VIIIA through VIIID in the online-only Data Supplement). Consistent with this staining pattern, EphA2 KO mice also show reduced staining for the smooth muscle marker gene smooth muscle myosin heavy chain in the atherosclerotic plaques ( Figure VIIIE and VIIIF in the online-only Data Supplement), suggesting that EphA2 expression affects smooth muscle incorporation into the atherosclerotic lesion. Although plaque angiogenesis is associated with advanced atherosclerotic plaques 21 and endothelial EphA2 contributes to angiogenesis, 22 we did not detect any differences in capillary density in either the plaque or vessel adventitia in EphA2 KO mice compared with EphA2 WT mice ( Figure IXA through IXD in the online-only Data Supplement).
EphA2 Shows Differential Expression During Vascular Smooth Muscle Phenotypic Modulation
Because vascular smooth muscle phenotypic modulation critically regulates atherosclerotic plaque progression, 2 we next sought to define whether EphA2 expression is altered during smooth muscle phenotypic modulation in vitro and in vivo. In cell culture, vascular smooth muscle cells maintain the contractile, quiescent phenotype in serumdepleted conditions but transition to a synthetic phenotype in response to serum (Figure XA through XD in the online-only Data Supplement). 23 Human coronary artery vascular smooth muscle cells (hCoASMCs) expressed several EphA receptors and ephrinA ligands, including EphA2, EphA4, EphA5, EphA7, ephrinA1, ephrinA4, and ephrinA5. Serum-induced transition to the synthetic phenotype promoted the mRNA expression of EphA receptors while reducing the expression of ephrinA ligands ( Figure 5G ) and promoted EphA2 protein expression in a dose-dependent and time-dependent manner ( Figure 5H and Figure XF and XG in the online-only Data Supplement). We observed a similar phenotypic transition in human aortic smooth muscle cells (hAoSMCs; Figure XIA through XIE in the onlineonly Data Supplement) associated with enhanced EphA2 expression ( Figure XIF in the online-only Data Supplement). In addition to serum, smooth muscle cells undergo phenotypic transition in response to a variety of extracellular matrix proteins, with basement membrane proteins (collagen IV, laminin) promoting the quiescent, contractile phenotype and plaque-associated interstitial matrix proteins (unpolymerized collagen I, fibronectin) promoting a synthetic phenotype. 24, 25 Like the smooth muscle response to serum, culturing either hCoASMCs or hAoSMCs on collagen I and fibronectin promoted EphA2 expression compared with cells on basement membrane proteins ( Figure 5I and Figure  XIG in the online-only Data Supplement). Consistent with in vitro models, plaque-associated smooth muscle cells Figure 5 Continued. polymerase chain reaction and normalized to GAPDH. Representative expression of each gene was determined, and a heat map was generated. H, EphA2 protein expression was determined by Western blot and normalized to GAPDH. n=4. I, hCoASMCs were plated onto tissue culture dishes coated with collagen I (40 µg/mL), collagen IV (20 µg/mL), fibronectin (FN; 10 µg/mL), or laminin (LN; 20 µg/mL) and cultured for 3 days in serum-free conditions. EphA2 protein expression was assessed by Western blotting and normalized to GAPDH. n=5. J and K, Smooth muscle EphA2 expression in atherosclerotic plaques was assessed by immunohistochemistry. Plaques from (J) the carotid artery of Apoe −/− mice fed a Western diet for 16 weeks or (K) grade V human atherosclerotic lesions from coronary arteries were stained for EphA2 (green) and smooth muscle cells (SMA; red). White arrows indicate medial smooth muscle cells. Scale bar=100 µm. n=4 to 5. Data are expressed as mean±SEM. Statistical comparisons were made with the Student t test (B, E, F, and H), 1-way ANOVA (I) with Bonferroni posttest, or χ 2 test (C) comparing early-stage (I and II) and advanced-stage (III and IV) plaques.
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(smooth muscle actin positive) showed enhanced EphA2 expression compared with medial smooth muscle cells in both murine carotid and human coronary atherosclerotic lesions ( Figure 5J and 5K) . Together, these data suggest that smooth muscle cells in the atherosclerotic plaque express EphA2.
EphA2 Depletion Reduces Proliferation and Matrix Remodeling in Atherosclerotic Plaques and Vascular Smooth Muscle Cells
During atherosclerotic progression, migration and proliferation of smooth muscle cells into the neointima A through D, EphA2 wild-type (WT) and EphA2 knockout (KO) mice were fed a Western diet for 16 weeks, and proliferation in the (A and B) innominate and (C and D) carotid arteries was assessed by staining for Ki67 (red). The number of Ki67-positive cells in the plaque or adventitia was assessed, and plaque borders are indicated with a white dotted line. Scale bar=100 µm. n=6 to 7. E through H, hCoASMCs treated with or without EphA2 siRNA were maintained in either serum-free or 1% serum-containing conditions overnight, and proliferation was assessed by (E and G) staining for Ki67 (red) or (F and H) treatment with BrdU (10 µmol/L) for 2 hours and staining for BrdU (red). The percentage of proliferating cells was determined for each condition. n=4. Scale bar=100 µm. I and J, hCoASMCs were plated onto collagen I (40 µg/mL), and a scratch was created. Wound closure was monitored by time-lapse imaging (3 regions per wound) for 18 hours. Wound closure was calculated as percent closure from t=0. J, Representative images from scratch wound assay. Scale bar=100 µm. contribute to plaque size. 2 Several known genetic loci for cardiovascular disease involve genes that regulate cell proliferation and carcinogenesis, 26, 27 and EphA2 upregulation contributes to proliferation in a variety of cancer models. 28, 29 Therefore, we sought to determine whether EphA2 expression affects proliferation within atherosclerotic lesions. Using Ki67 as a marker for proliferation, immunohistochemistry showed a significant reduction in proliferation within the atherosclerotic lesions of EphA2 KO mice compared with EphA2 WT mice in both the innominate (Figure 6A and 6B) and carotid ( Figure 6C and 6D ) arteries, and this reduction was apparent in both the plaque itself and vessel adventitia. Consistent with reduced proliferation in the absence of EphA2, siRNA-mediated EphA2 knockdown in hCoASMCs reduced both Ki67 staining ( Figure 6C and 6D) and BrdU incorporation ( Figure 6E and 6F) in response to serum. Similar reductions in smooth muscle Ki67 staining were observed in hAoSMCs and with a second siRNA construct (Figure XIIA through XIID in the online-only Data Supplement), and EphA2 knockdown was verified at both at the mRNA and protein level for both siRNAs (Figure XIIIA through XIIID in the onlineonly Data Supplement). In addition, time-lapse videomicroscopy of hCoASMC wound healing in the presence of 1% serum shows a significant reduction in scratch wound closure in EphA2 siRNA-treated cells that was apparent at 11 hours after scratch and maintained for at least 18 hours ( Figure 6G and 6H) , suggesting that maximal serum-induced proliferation and scratch wound closure require EphA2 expression.
In a variety of cancer models, enhanced EphA2 expression promotes activation of extracellular regulated kinase (ERK1/2) and Akt1, classic mitogenic signaling pathways, through ligand-independent receptor signaling. 30 To assess whether EphA2 expression affects mitogenic signaling in smooth muscle cells, we assessed serum-induced signaling responses after EphA2 knockdown with siRNA. hCoASMCs were serum deprived for 24 hours after EphA2 knockdown, followed by stimulation with serum either short term (120 minutes) or long term (24 hours). Although EphA2 knockdown did not affect the early induction of either ERK1/2 or Akt1 phosphorylation in response to serum (5-30 minutes), EphA2 depletion greatly diminished the sustained activation of these pathways at the later time points (Figure 7A  through 7C) . Similarly, lower levels of ERK1/2 and Akt1 phosphorylation were observed after 24 hours of serum stimulation in both hCoASMCs ( Figure 7D and 7E) and hAoSMCs ( Figure XIVA and XIVB in the online-only Data Supplement), consistent with a role for EphA2 in sustained activation of these pathways. Similarly, atherosclerotic plaques from EphA2 KO mice show reduced phospho-ERK1/2 ( Figure 7F and 7G) and phospho-Akt1 staining ( Figure 7H and 7I) in the innominate and carotid arteries ( Figure XIVC through XIVF in the onlineonly Data Supplement) in both the total plaque area and the smooth muscle actin-positive plaque area compared with EphA2 WT controls. Taken together, these results suggest that EphA2 deletion reduces smooth muscle mitogenic signaling, consistent with reductions in smooth muscle and plaque-associated proliferation.
Extracellular matrix deposition and remodeling by intraplaque vascular smooth muscle cells significantly contribute to atherosclerotic plaque progression. 31 Because EphA2 KO mice show reduced progression to advanced-stage plaques at 16 weeks of Western diet feeding ( Figure 5C Figure 8A and 8B) and polarized Picrosirius red staining ( Figure 8C and 8D) , and a reduction in plaque fibronectin levels ( Figure 8E and 8F) . In addition to reduced fibrous area in the plaque, the percent of plaque area staining positive for Masson trichrome, polarized Picrosirius red, and fibronectin was reduced in EphA2 KO mice ( Figure XVA through XVC) . Similar reductions in plaque collagen staining were observed in the aortic root of EphA2 KO mice, suggesting that this reduction in fibrous content extends across multiple vascular beds ( Figure XVI in the online-only Data Supplement). However, analysis of hCoASMC mRNA failed to identify significant differences in matrix gene expression after EphA2 knockdown in vitro ( Figure XVIIA in the online-only Data Supplement), although a trend for reduced fibronectin expression was observed on EphA2 depletion. To assess changes in matrix deposition, we isolated the deoxycholate-insoluble matrix from serumtreated smooth muscle cells with or without EphA2 knockdown. Consistent with the in vivo data, EphA2 depletion significantly reduced smooth muscle deposition of deoxycholate-insoluble fibronectin fibrils, including both total fibronectin ( Figure 8G and Figure  XVIIB and XVIID in the online-only Data Supplement) and cell-derived fibronectin containing the extradomain A alternative splice site ( Figure 8H and Figure XVIIC and XVIIE in the online-only Data Supplement) in both hCoASMCs and in hAoSMCs ( Figure XVIIIA through XVIIIC in the online-only Data Supplement). Because collagen deposition requires fibronectin polymerization in models of vascular injury, 32 our data suggest that EphA2 expression may modulate smooth muscledriven fibrosis in atherosclerotic plaques by regulating fibronectin deposition.
DISCUSSION
Early atherosclerotic plaques are dominated by inflammatory cross-talk between relatively few key cell types, which elicits endothelial cell activation, leukocyte re- cruitment, and smooth muscle invasion and fibroproliferative remodeling within the developing plaque. Many previous studies demonstrate that endothelial EphA2 expression is enhanced and activated during inflammatory contexts, including within the endothelium overlying atherosclerotic plaques. 6, 9, 33 Using the Apoe −/− model of atherogenesis, we now demonstrate that EphA2 deletion reduced atherosclerotic burden Multiple lines of evidence suggest that EphA2 contributes to inflammatory endothelial activation. EphA2 expression is enhanced in a variety of proinflammatory conditions, including atherosclerosis, acute lung injury, ischemia/reperfusion, and psoriasis, 6, [33] [34] [35] often concomitant with upregulation of its ligand ephrinA1. During early atherogenesis, endothelial activation promotes nuclear factor-κB-dependent ICAM-1 and VCAM-1 expression to facilitate leukocyte recruitment and extravasation. 36, 37 EphA2 deletion blunts nuclear factor-κB activation, endothelial permeability, and chemokine expression in lipopolysaccharide-induced lung injury models, 7, 38 and a study by Jiang et al 9 showed that infection of Apoe −/− mice with EphA2 shRNA reduced atherosclerotic lesions and diminished both nuclear factor-κB activation and proinflammatory gene expression. Atherosclerotic plaques in EphA2 KO mice similarly show reduced VCAM-1 and ICAM-1 expression compared with EphA2 WT mice ( Figure 2D ), indicating that EphA2 contributes to the endothelial proinflammatory phenotype in atherosclerosis. Eph/ephrin interactions also regulate leukocyte adhesion/repulsion responses and migration through control of integrin activation and cytoskeletal dynamics. 39, 40 Although EphA2 deletion does not affect TNF-α-induced proinflammatory gene expression, 6 EphA2-depleted endothelial cells show a reduced capacity to support monocyte firm adhesion after TNF-α treatment ( Figure 4G and Figure  VIB in the online-only Data Supplement). In addition, substrate-bound EphA2 significantly enhances both monocyte adhesion to recombinant ICAM-1/VCAM-1 and monocyte spreading on fibronectin ( Figure VII in the online-only Data Supplement). Monocyte adhesion and spreading are unaltered when recombinant ephrinA1 is added to the substrates ( Figure VIIA and VIIB in the online-only Data Supplement), further suggesting that monocytic EphA2 does not contribute to monocyte adhesion during leukocyte homing. However, EphA2 does not promote leukocyte recruitment under all contexts because monocyte recruitment during sterile (thioglycollate-elicited) inflammation remains unchanged in EphA2-deficient mice ( Figure 3B ). Collectively, these data indicate that endothelial EphA2 expression modulates endothelial-monocyte interactions through multiple mechanisms.
Progression from early fatty streaks to advanced atheromas involves the recruitment of vascular smooth muscle cells into the growing plaque, with fibroproliferative remodeling driving the formation of the protective fibrous cap. 1 To accomplish this, smooth muscle cells undergo a dynamic shift from a quiescent, contractile phenotype in the medial layer to a promigratory, proliferative, and profibrotic phenotype in the atherosclerotic plaque. We now show that smooth muscle transition to this activated phenotype results in the enhanced expression of EphA2 both in cell culture models and in atherosclerotic plaques ( Figure 5G through 5K) . Elevated EphA2 expression promotes proliferation and migration in several cancer models, 28, 29 and deletion of EphA2 reduces plaque progression, plaque smooth muscle content, and plaque-associated proliferation, as well as smooth muscle proliferation, mitogenic signaling (phospho-ERK1/2, phospho-Akt1), and scratch wound healing in culture (Figures 5 through 7) . Furthermore, deletion of EphA2 reduces plaque fibronectin and collagen content ( Figure 8A through 8F) , and EphA2 knockdown in vascular smooth muscle cells attenuates fibronectin deposition ( Figure 8G and 8H) . The reduced collagen content in EphA2-deficient plaques could result from reduced collagen degradation through proteases such as matrix metalloproteinase-2 and -9. Although EphA2 depletion enhances matrix metalloproteinase-2 and -9 mRNA expression, these proteases do not show changes in protein expression or activity after EphA2 knockdown ( Figure XIX in the online-only Data Supplement). Whereas EphA2 can promote fibronectin expression in cancer models, 41 EphA2 did not significantly affect smooth muscle matrix gene expression ( Figure IX in the onlineonly Data Supplement), although fibronectin expression was reduced, albeit insignificantly, on EphA2 silencing. Depletion of EphA2 reduces fibronectin deposition (Figure 8G and 8H and Figures XVII and XVIII in the onlineonly Data Supplement), and plating smooth muscle cells on a fibronectin matrix abrogates the effect of EphA2 deletion on smooth muscle scratch wound healing (Figure XX in the online-only Data Supplement), suggesting that EphA2-dependent fibronectin deposition may contribute to EphA2-dependent regulation of smooth muscle function. Because fibronectin drives vascular smooth muscle proliferation and migration, 25 EphA2-induced fibronectin deposition may promote a permissible environment for vascular smooth muscle infiltration into atherosclerotic lesions. Furthermore, this relationship between EphA2 and fibronectin may incur an unusual feed-forward response because fibronectin alone was shown to upregulate EphA2 expression independently of any other stimulus ( Figure 5I and Figure XIG in the online-only Data Supplement). Taken together, these data provide the first report of an EphA2-dependent transition to advanced atherosclerosis through the regulation of smooth muscle fibroproliferative remodeling.
EphA2 appears to play a complex role in the pathogenesis of atherosclerotic cardiovascular disease, with EphA2 deletion inducing opposing effects on plasma lipid levels and plaque formation. Although both male and female EphA2 KO mice display reduced plaque formation ( Figure 1A through 1D) , male EphA2 KO mice demonstrated significantly enhanced weight gain and plasma lipid levels when fed either standard chow or a high-fat Western diet ( Figure IIA through IID in the online-only Data Supplement). Because EphA2 expression does not affect macrophage lipid uptake and hematopoietic EphA2 deletion does not affect plasma lipid levels in bone marrow chimera (Figures IVC and V in the online-only Data Supplement), the effect of EphA2 deletion on plasma lipid levels may result from a previously unrecognized role for EphA2 in hepatocyte function. Whereas no studies to date have shown a role for EphA2 in metabolic abnormalities, the chromosomal region containing the EphA2 gene (1p36.13) is associated with the metabolic syndrome in multiple studies. [42] [43] [44] Furthermore, genome-wide association studies analysis links both EphA2 and ephrinA1 to the presence of liver enzymes in plasma, 45 and both EphA2 and ephrinA1 showed reduced expression in a rat model of nonalcoholic fatty liver disease. 46 Although assessment of the role of EphA2 in cholesterol transport responses should serve as an interesting direction for future research, the reduction in atherosclerotic plaque formation despite the elevations in plasma lipid levels underscores the important role of EphA2 signaling in vascular remodeling responses during atherogenesis.
The data shown herein highlight 2 opposing functions of EphA2 in atherosclerosis: the propagation of early atherogenic inflammation and the stabilization of late-stage plaques through fibroproliferative remodeling. However, recent publications highlight the often inverse function of EphA2 signaling resulting from differential ligand-dependent and ligand-independent signaling. Endothelial EphA2 relies on ephrinA1-dependent activation for proinflammatory marker expression 6 and likely interacts with ephrinA1 to promote monocyte firm adhesion ( Figure 4G and Figure VI in the online-only Data Supplement). Therefore, ligand-dependent signaling of endothelial EphA2 may contribute to early atherosclerosis by propagating atherogenic inflammation. Although EphA2 ligation inhibits proliferative signaling cascades, 47 enhanced expression of unligated EphA2 promotes migration and proliferation. 20, 48, 49 Unlike endothelial cells, mRNA analysis reveals a downregulation of ephrinA1 in the proliferative vascular smooth muscle phenotype ( Figure 5G) , suggesting a potential contribution of ligand-independent signaling from smooth muscle EphA2 in late-stage atherosclerosis. Therefore, pharmacological approaches that limit EphA2 liganddependent signaling (blocking antibodies, kinase inhibitors) may reduce the proinflammatory effects of EphA2 without inhibiting its beneficial effect on smooth muscle proliferation and extracellular matrix deposition.
